NCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
Clinical Trials
13 trialsNCT07338981 2026-01-14
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
British Columbia Cancer Agency
Phase 3 Not yet recruiting
NCT03391869 2025-12-17
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT06794775 2025-12-12
SWE-NEO
Karolinska University Hospital
Phase 3 Recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT03469960 2025-11-18
DICIPLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Completed
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT04949113 2024-03-08
NADINA
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT04741438 2023-08-30
RAR-Immune
Centre Leon Berard
Phase 3 Unknown
NCT03700905 2023-05-23
IMSTAR-HN
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Unknown
NCT03351361 2023-03-01
eNERGY
Rennes University Hospital
Phase 3 Completed
NCT02460068 2015-06-02
NIBIT-M2
Italian Network for Tumor Biotherapy Foundation
Phase 3 Unknown